Early detection of connective tissue disease in patients with Raynaud's phenomenonKALLENBERG, C. G. M.Rheumatic disease clinics of North America. 1990, Vol 16, Num 1, pp 11-30Article

Raynaud's phenomenon as an early sign of connective tissue diseasesKALLENBERG, C. G. M.Vasa. Supplementum. 1992, Vol 34, pp 25-28, issn 0251-1029Article

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: where to go?KALLENBERG, C. G. M.Clinical and experimental immunology (Print). 2011, Vol 164, pp 1-3, issn 0009-9104, 3 p., SUP1Conference Paper

A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiencyKALLENBERG, C. G. M.Clinical and experimental immunology (Print). 2007, Vol 150, Num 3, pp 437-441, issn 0009-9104, 5 p.Article

Autoantibodies in vasculitis : current perspectivesKALLENBERG, C. G. M.Clinical and experimental rheumatology (Testo stampato). 1993, Vol 11, Num 4, pp 355-360, issn 0392-856XArticle

Anti-neutrophil cytoplasm autoantibodies (ANCA) in autoimmune liver diseasesROOZENDAAL, C; KALLENBERG, C. G. M.Hepato-gastroenterology. 1999, Vol 46, Num 30, pp 3034-3040, issn 0172-6390Article

Clinical aspects of primary vasculitisSTEGEMAN, C. A; KALLENBERG, C. G. M.Springer seminars in immunopathology. 2001, Vol 23, Num 3, pp 231-251, issn 0344-4325Article

Laboratory findings in the vasculitidesKALLENBERG, C. G. M.Baillière's clinical rheumatology. 1997, Vol 11, Num 2, pp 395-421, issn 0950-3579Article

Hypoxia-Inducible Factor-1 as Regulator of Angiogenesis in Rheumatoid Arthritis - Therapeutic ImplicationsWESTRA, J; MOLEMA, G; KALLENBERG, C. G. M et al.Current medicinal chemistry. 2010, Vol 17, Num 3, pp 254-263, issn 0929-8673, 10 p.Article

Antitopoisomerase and anticentromere antibodies in the sclerodermatosus complexKALLENBERG, C. G. M.Clinical reviews in allergy. 1994, Vol 12, Num 3, pp 221-235, issn 0731-8235Article

Treatment of severe thrombocytopenia in systemic lupus erythematosus with intravenous gammaglobulinTER BORG, E. J; KALLENBERG, C. G. M.Annals of the rheumatic diseases. 1992, Vol 51, Num 10, pp 1149-1151, issn 0003-4967Article

Macrovascular disease and atherosclerosis in SScHETTEMA, M. E; BOOTSMA, H; KALLENBERG, C. G. M et al.Rheumatology (Oxford. Print). 2008, Vol 47, Num 5, pp 578-583, issn 1462-0324, 6 p.Article

Infections and Wegener's granulomatosis : a cause and effect relationship?GEORGE, J; LEVY, Y; KALLENBERG, C. G. M et al.QJM (Oxford. 1994. Print). 1997, Vol 90, Num 5, pp 367-373, issn 1460-2725Article

Interstitial lung disease and myositis in a patient with simultaneously occurring sarcoidosis and sclerodermaGROEN, H; POSTMA, D. S; KALLENBERG, C. G. M et al.Chest. 1993, Vol 104, Num 4, pp 1298-1300, issn 0012-3692Article

Vaccination of immune-compromised patients with the focus on patients with autoimmune-inflammatory diseasesBIJL, M; KALLENBERG, C. G. M; VAN ASSEN, S et al.Netherlands journal of medicine. 2011, Vol 69, Num 1, pp 5-13, issn 0300-2977, 9 p.Article

The cellular immune response to cell-associated and cell-free cytomegalovirus (CMV) antigens after primary CMV-infection in non-immunocompromised hosts: development and maintenance of CMV-latency and its influence on immunocompetenceROENHORST, H. W; KALLENBERG, C. G. M; THE, T. H et al.Clinical and experimental immunology (Print). 1988, Vol 74, Num 3, pp 326-332, issn 0009-9104, 7 p.Article

HLA and disease : past, present and futureDE VRIES, R. R. P.Netherlands journal of medicine. 1994, Vol 45, Num 6, pp 302-308, issn 0300-2977Article

B cell epitope specificity in ANCA-associated vasculitis: does it matter?VAN DER GELD, Y. M; STEGEMAN, C. A; KALLENBERG, C. G. M et al.Clinical and experimental immunology (Print). 2004, Vol 137, Num 3, pp 451-459, issn 0009-9104, 9 p.Article

Membrane proteinase 3 expression on resting neutrophils as a pathogenic factor in PR3-ANCA-associated vasculitisVAN ROSSUM, A. P; LIMBURG, P. C; KALLENBERG, C. G. M et al.Clinical and experimental rheumatology (Testo stampato). 2003, Vol 21, Num 6, pp S64-S68, issn 0392-856X, SUP32Article

Vascularites systémiques associées aux ANCA: Modèles animaux et leur intérêt clinique = Systemic vascularitis associated with ANCA : Animal models and their clinical interestWEENING, J. J; HEERINGA, P; BROUWER, E et al.Actualités néphrologiques Jean Hamburger. 1998, pp 51-65, issn 1168-1098Article

Co-trimoxazole and Wegener's granulomatosis: more than a coincidence?STEGEMAN, C. A; TERVAERT, J. W. C; KALLENBERG, C. G. M et al.Nephrology, dialysis, transplantation (Print). 1997, Vol 12, Num 4, pp 652-655, issn 0931-0509Conference Paper

Changes in plasma levels of interleukin-2 receptors in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosusTER BORG, E. J; HORST, G; LIMBURG, P. C et al.Clinical and experimental immunology (Print). 1990, Vol 82, Num 1, pp 21-26, issn 0009-9104, 6 p.Article

Type I interferons are involved in the development of ultraviolet B-induced inflammatory skin lesions in systemic lupus erythaematosus patientsFLEEFMAN, E; KUIPER, H; LIMBURG, P. C et al.Annals of the rheumatic diseases. 2008, Vol 67, Num 1, pp 11-18, issn 0003-4967, 8 p.Article

Anti-CD3-induced and anti-Fas-induced apoptosis in systemic lupus erythematosus (SLE)BIJL, M; HORST, G; LIMBURG, P. C et al.Clinical and experimental immunology (Print). 2001, Vol 123, Num 1, pp 127-132, issn 0009-9104Article

Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytesBIJL, M; HORST, G; LIMBURG, P. C et al.European journal of clinical investigation. 2001, Vol 31, Num 6, pp 550-553, issn 0014-2972Article